Sepsis patients display a reduced capacity to activate nuclear factor-κB in multiple cell types

Critical Care Medicine

Volumn 45, Issue 5, 2017, Pages e524-e531

  Hoogendijk, Arie J ^a,b   Garcia Laorden, M Isabel ^a,b   Van Vught, Lonneke A ^a,b   Wiewel, Maryse A ^a,b   Belkasim Bohoudi, Hakima ^a,b   Duitman, JanWillem ^a,b   Horn, Janneke ^a   Schultz, Marcus J ^a   Scicluna, Brendon P ^a,b   Vant Veer, Cornelis ^a,b   De Vos, Alex F ^a,b   Van Der Poll, Tom ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Center for Infection and Immunity Amsterdam   (Netherlands)

Author keywords

Immunosuppression; Nuclear factor ?b; Sepsis; Signaling; Whole blood stimulation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOID CELL; MALE; MONOCYTE; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEPSIS; SIGNAL TRANSDUCTION; UPREGULATION; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SEPSIS; SIGNAL TRANSDUCTION;

EID: 85014011514     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002294     Document Type: Article

References (42)

1. Cohen J, Vincent JL, Adhikari NK, et al: Sepsis: A roadmap for future research. Lancet Infect Dis 2015; 15:581-614.
2. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013; 369:840-851.
3. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-268.
4. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-874.
5. López-Collazo E, del Fresno C: Pathophysiology of endotoxin tolerance: Mechanisms and clinical consequences. Crit Care 2013; 17:242.
6. Ghosh S, Hayden MS: New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8:837-848.
7. Hayden MS, Ghosh S: NF-κB in immunobiology. Cell Res 2011; 21:223-244.
8. Collins PE, Kiely PA, Carmody RJ: Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor κB (NF-κB) p50. J Biol Chem 2014; 289:7059-7067.
9. Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
10. Viatour P, Merville MP, Bours V, et al: Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005; 30:43-52.
11. Yong HY, Koh MS, Moon A: The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 2009; 18:1893-1905.
12. Coulthard LR, White DE, Jones DL, et al: p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009; 15:369-379.
13. Klein Klouwenberg PM, Ong DS, Bos LD, et al: Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit Care Med 2013; 41:2373-2378.
14. Klein Klouwenberg PM, van Mourik MS, Ong DS, et al; MARS Consortium: Electronic implementation of a novel surveillance paradigm for ventilator-Associated events. Feasibility and validation. Am J Respir Crit Care Med 2014; 189:947-955.
15. Scicluna BP, Klein Klouwenberg PM, van Vught LA, et al: A molecular biomarker to diagnose community-Acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med 2015; 192:826-835.
16. Irish JM, Hovland R, Krutzik PO, et al: Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118:217-228.
17. Kawai T, Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-650.
18. Björk L, Tracey KJ, Ulrich P, et al: Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J Infect Dis 1997; 176:1303-1312.
19. Kaukonen KM, Bailey M, Suzuki S, et al: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311:1308-1316.
20. Angus DC: The search for effective therapy for sepsis: Back to the drawing board? JAMA 2011; 306:2614-2615.
21. Shih HC, Huang MS, Lee CH: Relation of signal in mononuclear cell with endotoxin response and clinical outcome after trauma. Am J Emerg Med 2012; 30:405-411.
22. Adib-Conquy M, Adrie C, Moine P, et al: NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 2000; 162:1877-1883.
23. Arnalich F, Garcia-Palomero E, López J, et al: Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000; 68:1942-1945.
24. Paterson RL, Galley HF, Dhillon JK, et al: Increased nuclear factor kappa B activation in critically ill patients who die. Crit Care Med 2000; 28:1047-1051.
25. Biberthaler P, Stegmaier J, Mayer V, et al: Initial posttraumatic translocation of NF-kappaB and TNF-Alpha mRNA expression in peripheral blood monocytes of trauma patients with multiple injuries: A pilot study. Shock 2004; 22:527-532.
26. Hotta N, Ichiyama T, Shiraishi M, et al: Nuclear factor-kappaB activation in peripheral blood mononuclear cells in children with sepsis. Crit Care Med 2007; 35:2395-2401.
27. Lord JM, Midwinter MJ, Chen YF, et al: The systemic immune response to trauma: An overview of pathophysiology and treatment. Lancet 2014; 384:1455-1465.
28. Nimah M, Zhao B, Denenberg AG, et al: Contribution of MKP-1 regulation of p38 to endotoxin tolerance. Shock 2005; 23:80-87.
29. Xiong Y, Medvedev AE: Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol 2011; 90:1141-1148.
30. Adib-Conquy M, Moine P, Asehnoune K, et al: Toll-like receptormediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med 2003; 168:158-164.
31. Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, et al: Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg 2014; 76:21-9; discussion 29.
32. Hamerman JA, Pottle J, Ni M, et al: Negative regulation of TLR signaling in myeloid cells-implications for autoimmune diseases. Immunol Rev 2016; 269:212-227.
33. Takekawa M, Tomida T, Saito H: Oscillation of p38 activity controls efficient pro-inflammatory gene expression. Nature Communications 2015; 6:1-9.
34. van Veer C, van den Pangaart PS, van Zoelen MAD, et al: Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007; 179:7110-7120.
35. Wiersinga WJ, van Veer C, van den Pangaart PS, et al: Immunosuppression associated with interleukin-1R-Associatedkinase- M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009; 37:569-576.
36. Wang D, Westerheide SD, Hanson JL, et al: Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000; 275:32592-32597.
37. Wang D, Baldwin AS Jr: Activation of nuclear factor-kappaBdependent transcription by tumor necrosis factor-Alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 1998; 273:29411-29416.
38. Manni S, Brancalion A, Mandato E, et al: Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One 2013; 8:e75280.
39. Kato T Jr, Delhase M, Hoffmann A, et al: CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV response. Mol Cell 2003; 12:829-839.
40. Singh NN, Ramji DP: Protein kinase CK2, an important regulator of the inflammatory response? J Mol Med (Berl) 2008; 86:887-897.
41. Yamada M, Katsuma S, Adachi T, et al: Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc Natl Acad Sci U S A 2005; 102:7736-7741.
42. Carmody RJ, Ruan Q, Palmer S, et al: Negative regulation of tolllike receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 2007; 317:675-678.